Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
    • 指導教授
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 社會科學院
  3. 經濟學系
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/94000
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor黃景沂zh_TW
dc.contributor.advisorChing-I Huangen
dc.contributor.author姚庚洋zh_TW
dc.contributor.authorKeng-Yang Yaoen
dc.date.accessioned2024-08-14T16:11:00Z-
dc.date.available2024-08-15-
dc.date.copyright2024-08-13-
dc.date.issued2024-
dc.date.submitted2024-07-31-
dc.identifier.citationAl-Dury, S. and Kanberg, N. (2024). Advancements in vaccine strategies for chronic liver disease patients: Navigating post-covid challenges and opportunities. Vaccines, 12(2):197.
Aw, J., Seng, J. J. B., Seah, S. S. Y., and Low, L. L. (2021). Covid-19 vaccine hesitancy—a scoping review of literature in high-income countries. Vaccines, 9(8):900.
Bio, S. (2021). Status of covid-19 vaccines within who eul/pq evaluation process. Guidance Document.
Bollyky, T. J., Castro, E., Aravkin, A. Y., Bhangdia, K., Dalos, J., Hulland, E. N., Kiernan, S., Lastuka, A., McHugh, T. A., Ostroff, S. M., et al. (2023). Assessing covid-19 pandemic policies and behaviours and their economic and educational trade-offs across us states from jan 1, 2020, to july 31, 2022: an observational analysis. The Lancet, 401(10385):1341–1360.
Cuadros, D. F., Branscum, A. J., Mukandavire, Z., Miller, F. D., and MacKinnon, N. (2021). Dynamics of the covid-19 epidemic in urban and rural areas in the united states. Annals of epidemiology, 59:16–20.
Dooling, K. (2021). The advisory committee on immunization practices’updated interim recommendation for allocation of covid-19 vaccine—united states, december 2020. MMWR. Morbidity and mortality weekly report, 69.
Duca, L. M., Coyle, J., McCabe, C., and McLean, C. A. (2020). Covid-19 stats: Covid-19 incidence, by urban-rural classification—us january 22–october 31, 2020.
Fajar, J. K., Sallam, M., Soegiarto, G., Sugiri, Y. J., Anshory, M., Wulandari, L., Kosasih, S. A. P., Ilmawan, M., Kusnaeni, K., Fikri, M., et al. (2022). Global prevalence and potential influencing factors of covid-19 vaccination hesitancy: a meta-analysis. Vaccines, 10(8):1356.
Fedeli, U., Amidei, C. B., Casotto, V., Grande, E., Saia, M., Zanetto, A., and Russo, F. P. (2023). Mortality from chronic liver disease: Recent trends and impact of the covid-19 pandemic. World Journal of Gastroenterology, 29(26):4166.
Fernandes, N., Costa, D., Costa, D., Keating, J., and Arantes, J. (2021). Predicting covid-19 vaccination intention: the determinants of vaccine hesitancy. Vaccines, 9(10):1161.
Fowler, J. H., Hill, S. J., Levin, R., and Obradovich, N. (2021). Stay-at-home orders associate with subsequent decreases in covid-19 cases and fatalities in the united states. PloS one, 16(6):e0248849.
Fuller, H., Dubbala, K., Obiri, D., Mallare, M., Advani, S., De Souza, S., Stoby, K., and King-Okoye, M. (2021). Addressing vaccine hesitancy to reduce racial and ethnic disparities in covid-19 vaccination uptake across the uk and us. Frontiers in public health, 9:789753.
Gee, J. (2021). First month of covid-19 vaccine safety monitoring—united states, december 14, 2020– january 13, 2021. MMWR. Morbidity and mortality weekly report, 70.
Golos, A. M., Hopkins, D. J., Bhanot, S. P., and Buttenheim, A. M. (2022). Partisanship, messaging, and the covid-19 vaccine: evidence from survey experiments. American Journal of Health Promotion, 36(4):602–611.
Haider, N., Hasan, M. N., Guitian, J., Khan, R. A., McCoy, D., Ntoumi, F., Dar, O., Ansumana, R., Uddin, M. J., Zumla, A., et al. (2023). The disproportionate case–fatality ratio of covid-19 between countries with the highest vaccination rates and the rest of the world. IJID regions, 6:159–166.
Hao, R., Zhang, Y., Cao, Z., Li, J., Xu, Q., Ye, L., Guo, X., Zheng, T., and Song, H. (2021). Control strategies and their effects on the covid-19 pandemic in 2020 in representative countries. Journal of biosafety and biosecurity, 3(2):76–81.
Harris, E. (2023). Most covid-19 deaths worldwide were among older people. Jama, 329(9):704–704. Hu, X., Sun, L., Guo, Z., Wu, C., Yu, X., and Li, J. (2022). Management of covid-19 patients with
chronic liver diseases and liver transplants. Annals of hepatology, 27(1):100653.
Khubchandani, J. and Macias, Y. (2021). Covid-19 vaccination hesitancy in hispanics and african-
americans: A review and recommendations for practice. Brain, behavior, & immunity-health, 15:100277.
Kompaniyets, L., Goodman, A. B., Belay, B., Freedman, D. S., Sucosky, M. S., Lange, S. J., Gundlapalli, A. V., Boehmer, T. K., and Blanck, H. M. (2021). Body mass index and risk for covid-19–related hos- pitalization, intensive care unit admission, invasive mechanical ventilation, and death—united states, march–december 2020. Morbidity and Mortality Weekly Report, 70(10):355.
Koskan, A. M., LoCoco, I. E., Daniel, C. L., and Teeter, B. S. (2023). Rural americans’covid-19 vac- cine perceptions and willingness to vaccinate against covid-19 with their community pharmacists: an exploratory study. Vaccines, 11(1):171.
Kotta, I., Kalcza-Janosi, K., Szabo, K., and Marschalko, E. E. (2022). Development and validation of the multidimensional covid-19 vaccine hesitancy scale. Human vaccines & immunotherapeutics, 18(1): 1–10.
Lin, C., Tu, P., and Beitsch, L. M. (2020). Confidence and receptivity for covid-19 vaccines: a rapid systematic review. Vaccines, 9(1):16.
Lips, A. (2021). The situation of young people at home during covid-19 pandemic. Childhood Vulnerability Journal, 3(1):61–78.
Long, J. D., Ward, C. A., and Khorasani-Zadeh, A. (2020). The impact of obesity on covid-19 disease severity. PRiMER: Peer-Review Reports in Medical Education Research, 4.
MacDonald, N. E. et al. (2015). Vaccine hesitancy: Definition, scope and determinants. Vaccine, 33(34): 4161–4164.
Maor, Y. and Caspi, S. (2022). Attitudes towards influenza, and covid-19 vaccines during the covid-19 pandemic among a representative sample of the jewish israeli population. Plos one, 17(2):e0255495.
Mostert, S., Hoogland, M., Huibers, M., and Kaspers, G. (2024). Excess mortality across countries in the western world since the covid-19 pandemic:‘our world in data’estimates of january 2020 to december 2022. BMJ Public Health, 2(1).
Nagarajan, R., Krishnamoorthy, Y., Rajaa, S., and Hariharan, V. S. (2022). Peer reviewed: Covid-19 severity and mortality among chronic liver disease patients: A systematic review and meta-analysis. Preventing chronic disease, 19.
Okubo, R., Yoshioka, T., Ohfuji, S., Matsuo, T., and Tabuchi, T. (2021). Covid-19 vaccine hesitancy and its associated factors in japan. Vaccines, 9(6):662.
Oliver, S. E., Wallace, M., Twentyman, E., Moulia, D. L., Godfrey, M., Link-Gelles, R., Meyer, S., Fleming-Dutra, K. E., Hall, E., Wolicki, J., et al. (2023). Development of covid-19 vaccine policy— united states, 2020–2023. Vaccine.
Ozdenerol, E. and Seboly, J. (2022). The effects of lifestyle on covid-19 vaccine hesitancy in the united states: an analysis of market segmentation. International journal of environmental research and public health, 19(13):7732.
Padamsee, T. J., Bond, R. M., Dixon, G. N., Hovick, S. R., Na, K., Nisbet, E. C., Wegener, D. T., and Garrett, R. K. (2022). Changes in covid-19 vaccine hesitancy among black and white individuals in the us. JAMA Network Open, 5(1):e2144470–e2144470.
Pecoraro, F., Clemente, F., and Luzi, D. (2020). The efficiency in the ordinary hospital bed management in italy: An in-depth analysis of intensive care unit in the areas affected by covid-19 before the outbreak. Plos one, 15(9):e0239249.
Rosenblum, H. G. (2021). Use of covid-19 vaccines after reports of adverse events among adult recipients of janssen (johnson & johnson) and mrna covid-19 vaccines (pfizer-biontech and moderna): update from the advisory committee on immunization practices—united states, july 2021. MMWR. Morbidity and mortality weekly report, 70.
Roy, D. N., Biswas, M., Islam, E., and Azam, M. S. (2022). Potential factors influencing covid-19 vaccine acceptance and hesitancy: A systematic review. PloS one, 17(3):e0265496.
Sallam, M. (2021). Covid-19 vaccine hesitancy worldwide: a concise systematic review of vaccine accep- tance rates. Vaccines, 9(2):160.
Salomon, J. A., Reinhart, A., Bilinski, A., Chua, E. J., La Motte-Kerr, W., Rönn, M. M., Reitsma, M. B., Morris, K. A., LaRocca, S., Farag, T. H., et al. (2021). The us covid-19 trends and impact survey: Continuous real-time measurement of covid-19 symptoms, risks, protective behaviors, testing, and vaccination. Proceedings of the National Academy of Sciences, 118(51):e2111454118.
Schinas, G., Polyzou, E., Mitropetrou, F., Pazionis, A., Gogos, C., Triantos, C., and Akinosoglou, K. (2022). Covid-19 vaccination in patients with chronic liver disease. Viruses, 14(12):2778.
Thangaraju, P. and Venkatesan, S. (2019). Who ten threats to global health in 2019: Antimicrobial resistance. Cukurova Medical Journal, 44(3):1150–1151.
Troiano, G. and Nardi, A. (2021). Vaccine hesitancy in the era of covid-19. Public health, 194:245–251. Varela, K. (2020). Primary indicators to systematically monitor covid-19 mitigation and response—
kentucky, may 19–july 15, 2020. MMWR. Morbidity and Mortality Weekly Report, 69.
Wang, B., Yuan, S., Ruan, S., Ning, X., Li, H., Liu, Y., and Li, X. (2023). Associations between underlying diseases with covid-19 and its symptoms among adults: a cross-sectional study. Frontiers in Public Health, 11:1210800.
Xiao, J., Cheung, J. K., Wu, P., Ni, M. Y., Cowling, B. J., and Liao, Q. (2022). Temporal changes in factors associated with covid-19 vaccine hesitancy and uptake among adults in hong kong: Serial cross-sectional surveys. The Lancet Regional Health–Western Pacific, 23.
Zhu, Y., Carroll, C., Vu, K., Sen, S., Georgiou, A., and Karaca-Mandic, P. (2023). Covid-19 hospitaliza- tion trends in rural versus urban areas in the united states. Medical Care Research and Review, 80(2): 236–244.
-
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/94000-
dc.description.abstract自從 2019 年 COVID-19 爆發後病毒迅速擴展到全球,導致一場持續性嚴重的疫情傳染,死亡率很高。各國為降低疫情帶來的影響,在疫情爆發之初就致力於疫苗研發,以因應這突如其來的災難。特別是美國受到該疫情影響甚巨,根據世界衛生組織2020年的統計,美國累計 COVID-19 確診病例數居世界各國之首。此外,由於美國是世界最大的經濟體,世界經濟也深受打擊。美國積極投入COVID-19 疫苗的研發生產並發揮主導作用,因此,疫苗很早就釋出,並提供足夠的可用劑量。然而,許多人對疫苗接種猶豫不決,導致美國的接種率相對較低。對此,我們更想了解週邊疫情的嚴峻程度,是否會讓人更願意面對疫苗緊急授權生產過程帶來的安全與有效性風險,從而更願意接種疫苗。
本論文分析了美國縣級的疫苗猶豫情況。分析各縣疫情擴散嚴峻程度對接受 COVID-19 疫苗意願的影響。然而,由於影響疫苗猶豫的未觀察到因素,最小平方法迴歸估算有遺漏變數偏誤,使用兩階段最小平方法解決內生性問題。我們的估算結果表明,當時各縣疫情擴散的嚴峻程度會影響個人接種疫苗的意願。
zh_TW
dc.description.abstractSince the COVID-19 outbreak in 2019, the virus spreaded to the whole world quickly, leading to a persistent and severe epidemic transmission with a high mortality rate. In order to reduce the impacts of the epidemic, countries have committed to the development of vaccines during the initial outbreak of the epidemic to respond this sudden disaster. In particular, the United States was seriously affected by the epidemic. According to the statistics of the World Health Organization in 2020, the cumulative number of COVID-19 confirmed cases in the United States ranked first among all countries in the world. In addition, since the United States was the largest economy in the world, the world economy was also deeply hit. The United States has actively invested in the research and production of COVID-19 vaccines and played a leading role. Therefore, the vaccine was released quite early with sufficient doses available. However, many people were hesitant about vaccination, resulting to a relatively low take-up rate in the United States. In this regard, we are curious to understand whether the severity of the surrounding epidemic would make people more willing to face the risks of safety and effectiveness brought about by the emergency authorized production process of vaccines, and hence more willing to get vaccinated.
This paper analyzes vaccine hesitancy at the county level in the United States. It analyzes the impact of the severity of the epidemic transmission in each county on the willingness to receive COVID-19 vaccines. However, due to unobserved factors that affect vaccine hesitancy, the least squares method (OLS) regression estimation has omitted variable bias. The endogenous problem is solved by using the two-stage least squares method (TSLS). Our estimation indicates that the severity of the epidemic spread in each county at that time would affected individual willingness to be vaccinated.
en
dc.description.provenanceSubmitted by admin ntu (admin@lib.ntu.edu.tw) on 2024-08-14T16:11:00Z
No. of bitstreams: 0
en
dc.description.provenanceMade available in DSpace on 2024-08-14T16:11:00Z (GMT). No. of bitstreams: 0en
dc.description.tableofcontentsAcknowledgements I
摘要 II
Abstract III
Contents IV
List of Figures V
List of Tables VI
1 Introduction 1
2 Literature Review 3
3 COVID-19 Vaccine Data 6
3.1 EpidemicSpread ......................................... 6
3.2 StatisticalData.......................................... 8
3.3 DependentVariableandExplanatoryVariables ........................ 10
3.4 ControlVariable ......................................... 13
4 Econometric Analysis 15
4.1 EndogeneityBias......................................... 15
4.2 InstrumentalVariables...................................... 15
4.3 InstrumentalVariablesDescription ............................... 17
4.4 InstrumentalVariablesAnalysis................................. 18
5 Estimation Results 20
5.1 RegressionAnalysis ....................................... 20
5.2 RobustnessTest ......................................... 24
6 Conclusion 31
Bibliography 33
-
dc.language.isoen-
dc.subject新冠肺炎zh_TW
dc.subject疫苗猶豫zh_TW
dc.subject疫苗授權zh_TW
dc.subject疫苗接種計畫zh_TW
dc.subject新冠肺炎疫苗zh_TW
dc.subjectvaccine authorizationen
dc.subjectvaccine hesitancyen
dc.subjectCOVID-19 vaccineen
dc.subjectCOVID-19en
dc.subjectvaccination planningen
dc.titleCOVID-19 疫情對美國疫苗猶豫的影響zh_TW
dc.titleThe impact of the COVID-19 pandemic on vaccine hesitancy in the United Statesen
dc.typeThesis-
dc.date.schoolyear112-2-
dc.description.degree碩士-
dc.contributor.oralexamcommittee樊家忠;朱建達zh_TW
dc.contributor.oralexamcommitteeElliott Fan;Jian-Da Zhuen
dc.subject.keyword新冠肺炎,新冠肺炎疫苗,疫苗猶豫,疫苗授權,疫苗接種計畫,zh_TW
dc.subject.keywordCOVID-19,COVID-19 vaccine,vaccine hesitancy,vaccine authorization,vaccination planning,en
dc.relation.page37-
dc.identifier.doi10.6342/NTU202402865-
dc.rights.note同意授權(限校園內公開)-
dc.date.accepted2024-08-02-
dc.contributor.author-college社會科學院-
dc.contributor.author-dept經濟學系-
dc.date.embargo-lift2024-12-31-
顯示於系所單位:經濟學系

文件中的檔案:
檔案 大小格式 
ntu-112-2.pdf
授權僅限NTU校內IP使用(校園外請利用VPN校外連線服務)
2.11 MBAdobe PDF
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved